Annexon, Inc.
NASDAQ:ANNXBiotechnology
-$0.04 today
- Market cap
- $576.73M
- Beta
- 1.18
- P/E (TTM)
- -4.8
- EPS (TTM)
- -$1.01
Volume 2.98M
Average 2.56M
ANNX EPS (Diluted)
Earnings per share assuming conversion of dilutive securities such as options and convertible instruments.
Annexon, Inc.NASDAQ: ANNX
EPS (Diluted) · Q1 FY2026 · quarter ended Mar 2026
EPS (Diluted) remains negative
Q1 FY2026 EPS (Diluted) was -$0.23, compared with -$0.37 a year earlier. Trailing-twelve-month EPS (Diluted) was -$1.22.
Context
- EPS (Diluted) grew in size in 1 of the last 3 fiscal years.
What to watch
Whether EPS (Diluted) reaches the consensus estimate from 7 analysts of -$0.95 (+28.8%) for the fiscal year ending Dec 2026, a step up from the -32.7% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$0.23+17.9% QoQ
- Last fiscal yearDec 2025
- -$1.34-32.7% YoY
- LTMMar 2026
- -$1.22-3.4% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +37.8% | +30.5% | -7.3 pp |
| 1 year | -32.7% | +28.8% | +61.5 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EPS (Diluted) history
USD · from the income statement
- Latest · FY2025
- (1.34) USD
- Year-over-year change
- -32.7%
| Period | Period end | EPS (Diluted) | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (1.34) | -32.7% |
| FY2024 | 2024-12-31 | (1.01) | +42.9% |
| FY2023 | 2023-12-31 | (1.77) | +31.9% |
| FY2022 | 2022-12-31 | (2.60) | +22.2% |
| FY2021 | 2021-12-31 | (3.34) | — |
EPS (Diluted) vs competitors
How ANNX compares with its peers on the latest reported figures
- Peers report in different currencies, so EPS (Diluted) is compared through growth and rates rather than absolute size.
- Its year-over-year change of -3.4% is the 8th highest of 11, against a peer median of +14.7%.
| Company | Period | LTM | YoY | 3-year CAGR |
|---|---|---|---|---|
| LTM Mar 2026 | $2.66 USD | +153.8% | — | |
| LTM Mar 2026 | -$0.56 USD | +59.7% | — | |
| LTM Mar 2026 | -€0.61 EUR | +19.6% | — | |
| LTM Mar 2026 | -CHF 0.66 CHF | -26.9% | — | |
| LTM Mar 2026 | -$1.08 USD | +78.0% | — | |
| LTM Mar 2026 | -$1.22 USD | -3.4% | — | |
| LTM Jun 2026 | -$2.17 USD | +13.5% | — | |
| LTM Sep 2026 | -$2.56 USD | +9.9% | — | |
| LTM Mar 2026 | -$2.82 USD | -35.6% | — | |
ALMSAlumis Inc. Common Stock | LTM Jun 2026 | -$3.8 USD | +15.9% | — |
| FY2025 | -€4.65 EUR | -66.1% | — | |
| Peer median (excluding ANNX) | — | +14.7% | — | |
Competitors are the stored peer set for ANNX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 3.45M | 3.69M |
| Gross Profit | 0 | 0 | 0 | (3.45M) | (3.69M) |
| Gross Margin | — | — | — | — | — |
| Research & Development | 100.07M | 112.5M | 113.76M | 119.45M | 184.7M |
| Selling, General & Admin | 30.65M | 30.95M | 28.02M | 34.63M | 31.71M |
| Operating Expenses | 130.71M | 145.6M | 143.72M | 150.62M | 212.72M |
| Depreciation & Amortization | 2.14M | 2.15M | 2.15M | 3.45M | 2.65M |
| EBITDA | (128.18M) | (139.8M) | (132.09M) | (134.75M) | (204.04M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (130.71M) | (145.6M) | (143.72M) | (154.07M) | (216.41M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 390K | 3.65M | 9.49M | 15.87M | 9.72M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 390K | 3.65M | 9.49M | 15.87M | 9.72M |
| Income Before Tax | (130.32M) | (141.95M) | (134.24M) | (138.2M) | (206.69M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (130.32M) | (141.95M) | (134.24M) | (138.2M) | (206.69M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (3.34) | (2.60) | (1.77) | (1.01) | (1.34) |
| EPS (Diluted) | (3.34) | (2.60) | (1.77) | (1.01) | (1.34) |
| Weighted Avg Shares | 38.32M | 54.67M | 75.67M | 137.4M | 155.11M |
| Weighted Avg Shares (Diluted) | 38.32M | 54.67M | 75.67M | 137.4M | 155.11M |
Annexon, Inc.
NASDAQ:ANNX
Intrinsic Alpha fair value
Locked
Current Price
$3.52
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.